Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080262
Status:
COMPLETED
Last Update Posted:
2017-01-30
First Post:
2004-03-25
Brief Title:
Novel Epothilone BMS-247550 in Patients With Metastatic Breast Cancer MBC
Sponsor:
R-Pharm
Organization:
R-Pharm
Study Overview
Official Title:
Phase II Study of Novel Epothilone BMS-247550 in Patients With MBC Who Are Refractory to an Anthracycline a Taxane and Capecitabine
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 Ixabepilone in women with metastatic breast cancer who are refractory to an anthracycline a taxane and capecitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None